NCT01770652View on ClinicalTrials.gov

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions
Renal Impairment
Interventions
DRUG

Deferiprone

Oral iron chelator

Trial Locations (2)

H1T2M4

Hôpital Maisonneuve-Rosemont, Montreal

H3P3P1

Algorithme Pharma Inc., Mount Royal

Sponsors

Lead Sponsor

ApoPharma
All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT01770652 - An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment | Biotech Hunter | Biotech Hunter